A Rare Case of Extramedullary Relapse of Multiple Myeloma Causing Bowel Obstruction by Bhardwaj, Prarthna V. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2019-04-11 
A Rare Case of Extramedullary Relapse of Multiple Myeloma 
Causing Bowel Obstruction 
Prarthna V. Bhardwaj 
Baystate Medical Center 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Diagnosis Commons, Digestive System Diseases Commons, Hematology Commons, 
Hemic and Lymphatic Diseases Commons, Neoplasms Commons, and the Oncology Commons 
Repository Citation 
Bhardwaj PV, Khanna S, Jawad MD, Ali SS. (2019). A Rare Case of Extramedullary Relapse of Multiple 
Myeloma Causing Bowel Obstruction. Open Access Articles. https://doi.org/10.1155/2019/4962678. 
Retrieved from https://escholarship.umassmed.edu/oapubs/4350 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Case Report
A Rare Case of Extramedullary Relapse of Multiple Myeloma
Causing Bowel Obstruction
Prarthna V. Bhardwaj ,1 Shrinkhala Khanna,2 Majd D. Jawad,3 and Syed S. Ali4
1Resident, Department of Internal Medicine, Baystate Medical Center, Springfield, MA, USA
2Assistant Professor, Department of Hematology/Oncology, UMass Medical Center, Worcester, MA, USA
3Resident, Department of Pathology, Baystate Medical Center, Springfield, MA, USA
4Assistant Professor, Department of Hematology Oncology, Baystate Medical Center, Springfield, MA, USA
Correspondence should be addressed to Prarthna V. Bhardwaj; prarthnabhardwaj@gmail.com
Received 8 January 2019; Accepted 18 March 2019; Published 11 April 2019
Academic Editor: Marie-Christine Kyrtsonis
Copyright © 2019 Prarthna V. Bhardwaj et al. +is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Extramedullary myeloma, defined by presence of plasma cells outside the bonemarrow, is a rare entity accounting for about 3–9% of
all cases. It usually is aggressive with a median survival of <6months. It is also associated with adverse prognostic factors including
17p deletions and high-risk gene profiles. While common extramedullary sites include bones, there have been several case reports of
hematogenous extramedullary myeloma to the liver, lungs, pancreas, breast, skin, and soft tissues. Extramedullary myeloma to the
mesentery is a rare entity with only a handful of cases reported. We present a case of 69-year-old man presenting with relapse of
multiple myeloma to the mesentery, resulting in bowel obstruction to highlight the various presentations of myeloma.
1. Introduction
Multiple myeloma is characterized by malignant pro-
liferation of plasma cells that usually produce a unique
monoclonal immunoglobulin or parts of it. Although it is an
incurable disease, there have been several advances in
treatment over the past two decades that have greatly im-
proved the overall survival.
+e most common presentation of multiple myeloma is
clonal expansion in the bone marrow. Roughly 3–9% of
patients have pathogenic clonal plasma cell infiltrates that
can be found at various anatomical sites, such as the liver,
kidney, breasts, testes, skin, lungs, bones, and other tissues
which is called extramedullary disease [1, 2].
Clinically, extramedullary disease can be characterized as
follows: tumormasses adjacent to bone and extending into soft
tissues; soft tissue or visceral tumors that are not connected to
the bone; or diffuse infiltration by plasma cells without any
obvious focal lesion [2, 3]. Extramedullary disease tends to
have an unfavorable prognosis with a significantly shorter
overall survival, even in the era of novel agents [4].
Mesenteric myeloma is a very rare condition with about
12 case reports on the same [5–11]. Here, we present a case of
extramedullary myeloma relapse, resulting in bowel ob-
struction which is a very rare entity and highlights its varied
presentation.
2. Case Presentation
A 69-year-old Caucasian male was referred to our hospital
with 3weeks of abdominal distension and worsening right
lower quadrant pain. He was diagnosed with IgG kappa
multiple myeloma four years prior to presentation. He was
initially treated with bortezomib/dexamethasone with
monthly zolendronic acid with good response initially;
however, a year after diagnosis, he was found to have disease
progression which manifested as a right radius fracture. His
regimen was switched to lenalidomide with dexamethasone
with good response and clinically depressed levels of par-
aproteins. After completion of 9months of therapy, he
underwent autologous stem cell transplant with high-dose
melphalan. 7months after bone marrow transplant, his
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disease progressed with involvement of pericardial fluid.
Salvage therapy was initiated with pomalidomide, borte-
zomib, and dexamethasone which was discontinued a year
later due to peripheral neuropathy; however, at the end of
treatment, there was no evidence of ongoing disease.
When the patient presented to our hospital, he had an
acute abdomen. Initial blood work revealed a normocytic
anemia with hemoglobin of 8.4 g/dl and elevated ESR of 44.
He also had acute kidney injury with creatinine of 3mg/dl
(baseline of 1.9mg/dl). CT scan of the abdomen and pelvis
revealed extensive stranding seen throughout the abdomen
within the peritoneal space with edema in the mesentery
(Figure 1).
He underwent an exploratory laparotomy which
revealed induration of the entire base of the mesentery and
retroperitoneum. He had an IgG level of 4407 units with
predominantly kappa light chains whose level was 4833 units
(kappa to lambda ratio 540). Pathology revealed extensive
Figure 1: CT scan of the abdomen without contrast revealing mesenteric thickening with edema.
(a) (b) (c)
(d) (e) (f)
Figure 2: (a) Bone marrow infiltrated by plasma cells. (b) Bone marrow immunohistochemistry revealing CD138 positive cells. (c) Bone
marrow immunohistochemistry positive for kappa light chains. (d) Bone marrow immunohistochemistry negative for lambda light chains.
Mesenteric invasion (e) by myeloma cells (10x) and (f) by plasma cells (40x).
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mesenteric infiltration by kappa restricted plasma cells
positive for CD138 on immunohistochemistry, without
evidence of amyloidosis. Bone marrow biopsy revealed a
30% involvement by plasma cells (Figures 2(a)–2(f)). Cy-
togenetics showed 1q22 duplication, trisomy 7 and 15, and
gain of 8q24.1. +e skeletal survey revealed lytic lesions in
the left femur and skull (Figures 3 and 4).
He was started on carfilzomib and dexamethasone
therapy for relapsed multiple myeloma. Unfortunately, he
died within one day of start of the chemotherapy from
surgical complications of bowel obstruction.
3. Discussion
Extramedullary disease is common at the time of relapse in
multiple myeloma. At the time of relapse, there is no ra-
tionale to favor a specific therapeutic class of drugs. Previous
lines of therapy and the duration of response should clearly
be considered. We treated with carfilzomib (CFZ), a second-
generation proteasome inhibitor. Stewart et al. in their study
noted that the progression-free survival (PFS) was signifi-
cantly improved with CFZ (median, 26.3months vs.
17.6months in control group) especially among patients
previously treated with bortezomib and lenalidomide and in
patients with high-risk cytogenetics (defined by the presence
of t (4; 14) and t (14; 16) or deletion 17p) [12].
Our case is the one of few case reports of a patient
presenting with an abdominal catastrophe from relapsed
multiple myeloma, causing tethering of the bowel loops due
to plasma cell infiltration in the peritoneum.
As patients live longer with myeloma, multiple relapses
may occur from different subclones of plasma cells, and this
may be the reason for the more frequent occurrence of
extramedullary relapse observed today. PET/CT may have
role in close follow-up of patients with extramedullary
symptoms.
In conclusion, although extramedullary plasmacytomas
occur mainly in the upper aerodigestive tract, mesentery
may also be involved with very few case reports in the
current literature. +e sound combination of radiological,
laboratory, and histopathological workup leads to the cor-
rect diagnosis for a disease with diverse presentations.
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